Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon, a provider of drug development and manufacturing services, has relaunched its alliance with Depomed, a specialty pharmaceutical company, to provide development and commercialization service offerings.
Subscribe to our email newsletter
The partnership of Patheon and Depomed unites the company’s proprietary AcuForm delivery technology with Patheon’s extensive network of manufacturing and distribution facilities across the globe.
AcuForm is a patented, polymer-based technology designed to optimize drug delivery through gastric retention. AcuForm technology enables targeted, extended release of pharmaceutical ingredients to the upper gastrointestinal tract. This allows increased bioavailability, less frequent dosing and fewer side effects than presently seen with other formulations.
Wes Wheeler, CEO of Patheon, said: “The alliance between Patheon and Depomed unites Patheon’s global network of manufacturing and distribution facilities while enhancing our commercial services to our customers. The convenience of once-daily administration, and improved treatment tolerability of the AcuForm, technology, will enhance the services we can provide to our customers.”